Myeloma xenograft growth and post-treatment regrowth
Animal study · Immune-deficient beige-nude-xid mice bearing subcutaneous MM.1S human multiple-myeloma xenografts. [1]
Daily oral pazopanib delayed tumor growth at 30 mg/kg and almost completely inhibited growth during treatment at 100 mg/kg relative to vehicle. Tumors rapidly regrew after treatment stopped. These observations do not establish durable eradication.
| Endpoint | Reported result | Reference |
|---|---|---|
| Tumor-volume trajectory | qualitative reported outcome 30 mg/kg: delayed growth; 100 mg/kg: almost total inhibition during treatment versus vehicle | [1] |
| Tumor response after cessation | qualitative reported outcome Rapid regrowth after treatment stopped at day 30, as described in Results | [1] |
| Body-weight monitoring | qualitative reported outcome No effect on body weight reported for vehicle or pazopanib groups | [1] |
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Daily
- Treatment course
- Results describes administration over five weeks, but also states cessation at day 30; Figure 4b marks treatment stop at about day 30. These descriptions are not harmonized.
- Vehicle
- 0.5% hydroxypropylmethyl cellulose and 0.1% Tween-80 in water, pH 1.3–1.5.
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Vehicle control | Vehicle alone on the same schedule and route | Reference tumor-growth and body-weight group. | [1] |
| Pazopanib 30 mg/kg | Vehicle alone on the same schedule and route | Tumor growth delayed; regrowth after treatment stopped. | [1] |
| Pazopanib 100 mg/kg | Vehicle alone on the same schedule and route | Growth almost totally inhibited during treatment; regrowth after treatment stopped. | [1] |
- Vehicle control
- Model: Immune-deficient beige-nude-xid mice bearing subcutaneous MM.1S human multiple-myeloma xenografts.
- Reported limits: Group size not specified in the reviewed methods/caption; exact course wording inconsistent.
- Pazopanib 30 mg/kg
- Model: Immune-deficient beige-nude-xid mice bearing subcutaneous MM.1S human multiple-myeloma xenografts.
- Reported limits: Group size not specified in the reviewed methods/caption; exact course wording inconsistent.
- Pazopanib 100 mg/kg
- Model: Immune-deficient beige-nude-xid mice bearing subcutaneous MM.1S human multiple-myeloma xenografts.
- Reported limits: Group size not specified in the reviewed methods/caption; exact course wording inconsistent.
Methods and source locations
Compound reported in the paper: Pazopanib; Compound label in the paper: GW786034B
Qualitative xenograft findings for the authors’ reported pazopanib monohydrochloride. Doses are retained as reported, without salt conversion. No A10699 lot performance, clinical efficacy or direct causal mechanism is established.
Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Tumor-volume trajectory: Caliper tumor volumes every other day; body weight three times weekly. Figure 4a reports means ± SE; no values digitized. — Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Tumor response after cessation: Caliper tumor volumes every other day; body weight three times weekly. Figure 4a reports means ± SE; no values digitized. — Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Body-weight monitoring: Caliper tumor volumes every other day; body weight three times weekly. Figure 4a reports means ± SE; no values digitized. — Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Vehicle control · Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Pazopanib 30 mg/kg · Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis
Pazopanib 100 mg/kg · Materials and Methods, Materials (section sec12); MM Xenograft Mouse Model; Results, Pazopanib Prolongs Survival; Figure 4a–c and caption; Statistical Analysis